{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:36:18Z","timestamp":1792618578216,"version":"4.5.0"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Negative symptoms of schizophrenia are a major contributor to poor outcomes, yet no US Food and Drug Administration\u2013approved pharmacotherapies are specifically indicated for their treatment. In particular, motivation and pleasure negative symptoms are especially burdensome for patients. Psychosocial interventions can be effective, but access barriers and challenges in sustaining engagement limit their impact. Digital therapeutics are a novel modality that can deliver patient-centered interventions. CT-155\/BI 3972080 (CT-155), an investigational smartphone-based digital therapeutic integrating evidence-based psychosocial strategies, is designed to address negative symptoms of schizophrenia adjunctive to pharmacotherapy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the effectiveness and safety of CT-155 as an adjunct to pharmacotherapy for negative symptoms of schizophrenia.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n CONVOKE was a phase 3, multicenter, double-blind, parallel-group, randomized clinical trial conducted between March 31, 2023, and June 20, 2025, at 66 clinical sites in the US among adults with negative symptoms of schizophrenia who were receiving up to 2 antipsychotic medications.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized 1:1 to CT-155 or a digital control for 16 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was change from baseline to week 16 in Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure subscale (CAINS-MAP) score. Secondary end points included change from baseline to week 16 in Positive and Negative Syndrome Scale positive subscale scores. All baseline demographic and clinical characteristic, effectiveness, and engagement analyses were performed using the intention-to-treat set.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 457 participants were randomized (227 to CT-155 and 230 to digital control; mean [SD] age, 45.8 [12.5] years; 277 male [60.6%]). Retention analyses showed that most participants stayed active in CT-155 (70.4%; [160 of 227]) or digital control (76.5% [176 of 230]) through the end of week 15. At week 16, CT-155 significantly reduced mean (SE) CAINS-MAP total score vs digital control (CT-155 [n\u2009=\u2009196], \u22126.8 (0.5); digital control [n\u2009=\u2009204], \u22124.2 (0.5); least-squares difference, \u22122.6 [95% CI, \u22124.0 to \u22121.2];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; Cohen\n d<\/jats:italic>\n , \u22120.36 [95% CI, \u20130.56 to \u20130.17]). During the 16-week intervention and 4-week follow-up, serious adverse events occurred in 3 of 228 participants (1.3%) receiving CT-155 and 5 of 231 (2.2%) receiving digital control; none were treatment related.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, CT-155 improved motivation and pleasure negative symptoms with a small-to-moderate effect size comparable with psychosocial interventions and pharmacologic treatment in psychiatry and was well tolerated and safe, thus representing a novel adjunctive therapy for schizophrenia. CT-155 may represent a scalable, accessible option for improving schizophrenia negative symptoms.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05838625<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.35753","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:30:29Z","timestamp":1790350229000},"page":"e2635753","source":"Crossref","is-referenced-by-count":1,"title":["A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia"],"prefix":"10.1001","volume":"9","author":[{"given":"Abhishek","family":"Pratap","sequence":"first","affiliation":[{"name":"Global Clinical Development Mental Health and Eye Health, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen E.","family":"Lakhan","sequence":"additional","affiliation":[{"name":"Medical & Clinical Development Department, Click Therapeutics Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Snipes","sequence":"additional","affiliation":[{"name":"Medical & Clinical Development Department, Click Therapeutics Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Tang","sequence":"additional","affiliation":[{"name":"Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olya","family":"Besedina","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Click Therapeutics Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Dickerson","sequence":"additional","affiliation":[{"name":"Psychology, Research and Education, Sheppard Pratt Health System, Towson, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"additional","affiliation":[{"name":"Psychopharmacology Research Unit, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Winderbaum Fernandez","sequence":"additional","affiliation":[{"name":"Interventional Psychiatry of Tampa Bay Clinical Research, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg W.","family":"Mattingly","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Torous","sequence":"additional","affiliation":[{"name":"Division of Digital Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Georgia, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Speier","sequence":"additional","affiliation":[{"name":"Regulatory Department, Click Therapeutics Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"von der Goltz","sequence":"additional","affiliation":[{"name":"Global Clinical Development Mental Health and Eye Health, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dorner-Ciossek","sequence":"additional","affiliation":[{"name":"Neuroscience & Mental Health Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"zoi260965r1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment.","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"zoi260965r2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.schres.2025.03.032","article-title":"Negative symptoms in psychosis: a scoping review of qualitative studies.","volume":"279","author":"Lyne","year":"2025","journal-title":"Schizophr Res"},{"issue":"1","key":"zoi260965r4","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2023.2478","article-title":"External validation of the five domains of negative symptoms: focus on cognition, functional capacity, and real-world functioning.","volume":"67","author":"Giordano","year":"2023","journal-title":"Eur Psychiatry"},{"issue":"1","key":"zoi260965r6","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2019.8","article-title":"Schizophrenia and \u201cunmet needs\u201d: from diagnosis to care in Italy.","volume":"63","author":"Galderisi","year":"2020","journal-title":"Eur Psychiatry"},{"issue":"3","key":"zoi260965r7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajp.2012.06.002","article-title":"Outcomes that matter: a qualitative study with persons with schizophrenia and their primary caregivers in India.","volume":"5","author":"Balaji","year":"2012","journal-title":"Asian J Psychiatr"},{"issue":"5","key":"zoi260965r8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/hex.12548","article-title":"The role of life context and self-defined well-being in the outcomes that matter to people with a diagnosis of schizophrenia.","volume":"20","author":"Lloyd","year":"2017","journal-title":"Health Expect"},{"issue":"1","key":"zoi260965r9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41537-023-00358-9","article-title":"A qualitative of stable symptomatology for patients with schizophrenia: do they have adequate post-discharge rehabilitative resources?","volume":"9","author":"Sun","year":"2023","journal-title":"Schizophrenia (Heidelb)"},{"issue":"5","key":"zoi260965r10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/schbul\/sbq068","article-title":"Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.","volume":"36","author":"Barch","year":"2010","journal-title":"Schizophr Bull"},{"key":"zoi260965r11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev-clinpsy-050212-185538","article-title":"Emotion deficits in people with schizophrenia.","volume":"9","author":"Kring","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"issue":"5","key":"zoi260965r12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/070674370505000503","article-title":"The negative symptoms of schizophrenia: a cognitive perspective.","volume":"50","author":"Rector","year":"2005","journal-title":"Can J Psychiatry"},{"issue":"3","key":"zoi260965r13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/17456916231197980","article-title":"Experimental therapeutics: opportunities and challenges stemming from the National Institute of Mental Health workshop on novel target discovery and psychosocial intervention development.","volume":"20","author":"Zucker","year":"2025","journal-title":"Perspect Psychol Sci"},{"issue":"3","key":"zoi260965r14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/schbul\/sbx099","article-title":"Improvement in negative symptoms and functioning in cognitive-behavioral social skills training for schizophrenia: mediation by defeatist performance attitudes and asocial beliefs.","volume":"44","author":"Granholm","year":"2018","journal-title":"Schizophr Bull"},{"key":"zoi260965r15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.schres.2025.01.014","article-title":"Using pupillometry to predict outcome in cognitive behavioral therapy for negative symptoms of schizophrenia.","volume":"276","author":"Delay","year":"2025","journal-title":"Schizophr Res"},{"issue":"5","key":"zoi260965r16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1192\/bjp.bp.116.197103","article-title":"Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis.","volume":"210","author":"Lutgens","year":"2017","journal-title":"Br J Psychiatry"},{"issue":"1","key":"zoi260965r17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bjp.2023.21","article-title":"Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses.","volume":"223","author":"Cella","year":"2023","journal-title":"Br J Psychiatry"},{"issue":"3","key":"zoi260965r18","doi-asserted-by":"publisher","DOI":"10.32872\/cpe.v2i3.2899","article-title":"Efficacy of psychological treatments for patients with schizophrenia and relevant negative symptoms: a meta-analysis.","volume":"2","author":"Riehle","year":"2020","journal-title":"Clin Psychol Eur"},{"issue":"4","key":"zoi260965r19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40596-021-01509-9","article-title":"Growing the psychiatry workforce through expansion or creation of residencies and fellowships: the results of a survey by the AADPRT Workforce Task Force.","volume":"46","author":"Pheister","year":"2022","journal-title":"Acad Psychiatry"},{"issue":"6","key":"zoi260965r21","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.amepre.2018.01.004","article-title":"Geographic variation in the supply of selected behavioral health providers.","volume":"54","author":"Andrilla","year":"2018","journal-title":"Am J Prev Med"},{"issue":"2","key":"zoi260965r22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1529100614531398","article-title":"The impact of mental illness stigma on seeking and participating in mental health care.","volume":"15","author":"Corrigan","year":"2014","journal-title":"Psychol Sci Public Interest"},{"issue":"1","key":"zoi260965r23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00127-013-0729-4","article-title":"Stigma in patients with schizophrenia receiving community mental health care: a review of qualitative studies.","volume":"49","author":"Mestdagh","year":"2014","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"3","key":"zoi260965r24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1037\/a0012801","article-title":"Self-determination theory: a macrotheory of human motivation, development, and health.","volume":"49","author":"Deci","year":"2008","journal-title":"Can Psychol"},{"issue":"1","key":"zoi260965r25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12793\/tcp.2019.27.1.6","article-title":"Digital therapeutics and clinical pharmacology.","volume":"27","author":"Chung","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"zoi260965r26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.schres.2018.11.026","article-title":"Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital.","volume":"206","author":"Achtyes","year":"2019","journal-title":"Schizophr Res"},{"issue":"2","key":"zoi260965r27","doi-asserted-by":"publisher","DOI":"10.2196\/mental.5379","article-title":"Digital technology use among individuals with schizophrenia: results of an online survey.","volume":"3","author":"Gay","year":"2016","journal-title":"JMIR Ment Health"},{"issue":"4","key":"zoi260965r28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1037\/prj0000207","article-title":"How people with serious mental illness use smartphones, mobile apps, and social media.","volume":"39","author":"Naslund","year":"2016","journal-title":"Psychiatr Rehabil J"},{"issue":"12","key":"zoi260965r29","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1038\/s41591-024-03252-8","article-title":"Digital AVATAR therapy for distressing voices in psychosis: the phase 2\/3 AVATAR2 trial.","volume":"30","author":"Garety","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"zoi260965r30","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1038\/s41591-025-03880-8","article-title":"Virtual reality\u2013based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trial.","volume":"31","author":"Jeppesen","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"zoi260965r31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/schbul\/sby078","article-title":"Efficacy of PRIME, a mobile app intervention designed to improve motivation in young people with schizophrenia.","volume":"44","author":"Schlosser","year":"2018","journal-title":"Schizophr Bull"},{"issue":"6","key":"zoi260965r32","doi-asserted-by":"publisher","DOI":"10.2196\/27475","article-title":"Preliminary outcomes of an ecological momentary intervention for social functioning in schizophrenia: pre-post study of the Motivation and Skills Support app.","volume":"8","author":"Fulford","year":"2021","journal-title":"JMIR Ment Health"},{"issue":"1","key":"zoi260965r33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jbct.2020.03.016","article-title":"Development of the Motivation and Skills Support (MASS) social goal attainment smartphone app for (and with) people with schizophrenia.","volume":"30","author":"Fulford","year":"2020","journal-title":"J Behav Cogn Ther"},{"issue":"10","key":"zoi260965r34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1037\/ccp0000599","article-title":"Mobile enhancement of motivation in schizophrenia: a pilot randomized controlled trial of a personalized text message intervention for motivation deficits.","volume":"88","author":"Luther","year":"2020","journal-title":"J Consult Clin Psychol"},{"issue":"12","key":"zoi260965r35","doi-asserted-by":"publisher","DOI":"10.2196\/24406","article-title":"Mobile-assisted cognitive behavioral therapy for negative symptoms: open single-arm trial with schizophrenia patients.","volume":"7","author":"Granholm","year":"2020","journal-title":"JMIR Ment Health"},{"issue":"4","key":"zoi260965r36","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaf134","article-title":"Digital therapeutics for people with schizophrenia spectrum disorders: a systematic literature review of their effect on symptoms and functioning.","volume":"52","author":"Fulford","year":"2026","journal-title":"Schizophr Bull"},{"issue":"1","key":"zoi260965r37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41537-025-00659-1","article-title":"Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study.","volume":"11","author":"Goenjian","year":"2025","journal-title":"Schizophrenia (Heidelb)"},{"key":"zoi260965r38","doi-asserted-by":"publisher","DOI":"10.2196\/81293","article-title":"Effectiveness, engagement, and safety of a digital therapeutic (CT-155\/BI 3972080) for treating negative symptoms in people with schizophrenia: protocol for the phase 3 CONVOKE randomized controlled trial.","volume":"14","author":"Lakhan","year":"2025","journal-title":"JMIR Res Protoc"},{"key":"zoi260965r39","doi-asserted-by":"publisher","DOI":"10.2196\/64959","article-title":"Establishment and maintenance of a digital therapeutic alliance in people living with negative symptoms of schizophrenia: two exploratory single-arm studies.","volume":"12","author":"Snipes","year":"2025","journal-title":"JMIR Ment Health"},{"issue":"1","key":"zoi260965r40","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgaf028","article-title":"Patient perspectives on a digital therapeutic for schizophrenia: a qualitative evaluation of an app for negative symptoms.","volume":"6","author":"Gandhi","year":"2025","journal-title":"Schizophr Bull Open"},{"issue":"4","key":"zoi260965r41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3988\/jcn.2024.0148","article-title":"Behavioral activation and brain network changes in depression.","volume":"20","author":"Jung","year":"2024","journal-title":"J Clin Neurol"},{"issue":"2","key":"zoi260965r42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0145445518805682","article-title":"Reward network modulation as a mechanism of change in behavioral activation.","volume":"44","author":"Nagy","year":"2020","journal-title":"Behav Modif"},{"key":"zoi260965r43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jad.2024.09.084","article-title":"Brain functional effects of cognitive behavioral therapy for depression: a systematic review of task-based fMRI studies.","volume":"368","author":"K\u00f6nig","year":"2025","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi260965r45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s40359-022-00879-5","article-title":"Goal setting with young people for anxiety and depression: what works for whom in therapeutic relationships? a literature review and insight analysis.","volume":"10","author":"Jacob","year":"2022","journal-title":"BMC Psychol"},{"issue":"4","key":"zoi260965r46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1037\/pst0000170","article-title":"Meta-analyses of the relation of goal consensus and collaboration to psychotherapy outcome.","volume":"55","author":"Tryon","year":"2018","journal-title":"Psychotherapy (Chic)"},{"key":"zoi260965r47","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3389\/fpsyg.2016.01759","article-title":"Motivational and behavioral activation as an adjunct to psychiatric rehabilitation for mild to moderate negative symptoms in individuals with schizophrenia: a proof-of-concept pilot study.","volume":"7","author":"Choi","year":"2016","journal-title":"Front Psychol"},{"key":"zoi260965r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnsa.2023.100132","article-title":"Efficacy of behavioural activation in the treatment of negative symptoms in people with schizophrenia spectrum disorders: a systematic review.","volume":"5","author":"Muyambi","year":"2023","journal-title":"Int J Nurs Stud Adv"},{"issue":"4","key":"zoi260965r49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/schbul\/sbn008","article-title":"Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia.","volume":"35","author":"Grant","year":"2009","journal-title":"Schizophr Bull"},{"issue":"1","key":"zoi260965r50","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.13","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia.","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry"},{"issue":"6","key":"zoi260965r51","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1037\/a0037098","article-title":"Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms.","volume":"82","author":"Granholm","year":"2014","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"zoi260965r52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1037\/0022-006X.76.3.491","article-title":"A meta-analysis of controlled research on social skills training for schizophrenia.","volume":"76","author":"Kurtz","year":"2008","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"zoi260965r53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/schbul\/sbab126","article-title":"Integrated cognitive-behavioral social skills training and compensatory cognitive training for negative symptoms of psychosis: effects in a pilot randomized controlled trial.","volume":"48","author":"Granholm","year":"2022","journal-title":"Schizophr Bull"},{"issue":"2","key":"zoi260965r54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000496479","article-title":"Improving pleasure and motivation in schizophrenia: a randomized controlled clinical trial.","volume":"88","author":"Favrod","year":"2019","journal-title":"Psychother Psychosom"},{"key":"zoi260965r55","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12888-015-0610-y","article-title":"Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy.","volume":"15","author":"Favrod","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"9","key":"zoi260965r56","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jclp.22944","article-title":"Levels of distress tolerance in schizophrenia appear equivalent to those found in borderline personality disorder.","volume":"76","author":"Bonfils","year":"2020","journal-title":"J Clin Psychol"},{"key":"zoi260965r57","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi260965r58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation.","volume":"170","author":"Kring","year":"2013","journal-title":"Am J Psychiatry"},{"key":"zoi260965r59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.schres.2017.01.011","article-title":"Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study.","volume":"185","author":"Blanchard","year":"2017","journal-title":"Schizophr Res"},{"issue":"2","key":"zoi260965r60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms.","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"issue":"2-3","key":"zoi260965r61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.schres.2011.06.030","article-title":"Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS).","volume":"132","author":"Horan","year":"2011","journal-title":"Schizophr Res"},{"issue":"2","key":"zoi260965r62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"12","key":"zoi260965r63","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"282","key":"zoi260965r64","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"zoi260965r65","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796019000891","article-title":"Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017.","volume":"29","author":"He","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"1","key":"zoi260965r66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/acps.13254","article-title":"Employment among people with schizophrenia or bipolar disorder: a population-based study using nationwide registers.","volume":"143","author":"Holm","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"zoi260965r67","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14458","article-title":"The economic burden of schizophrenia in the United States.","volume":"83","author":"Kadakia","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi260965r68","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2022-100823","article-title":"A glimpse of gender differences in schizophrenia.","volume":"35","author":"Li","year":"2022","journal-title":"Gen Psychiatr"},{"issue":"1","key":"zoi260965r69","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1037\/abn0000309","article-title":"Meta-analysis of Black vs. White racial disparity in schizophrenia diagnosis in the United States: do structured assessments attenuate racial disparities?","volume":"127","author":"Olbert","year":"2018","journal-title":"J Abnorm Psychol"},{"issue":"1","key":"zoi260965r70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.","volume":"21","author":"Leichsenring","year":"2022","journal-title":"World Psychiatry"},{"issue":"10128","key":"zoi260965r71","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"zoi260965r72","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jpsychires.2013.01.015","article-title":"Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.","volume":"47","author":"Strauss","year":"2013","journal-title":"J Psychiatr Res"},{"key":"zoi260965r73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.schres.2017.06.001","article-title":"The role of experiential and expressive negative symptoms on job obtainment and work outcome in individuals with schizophrenia.","volume":"192","author":"Llerena","year":"2018","journal-title":"Schizophr Res"},{"issue":"1","key":"zoi260965r74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1037\/0003-066X.55.1.68","article-title":"Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being.","volume":"55","author":"Ryan","year":"2000","journal-title":"Am Psychol"},{"key":"zoi260965r3","unstructured":"DailyMed search: \u201cschizophrenia\u201d AND \u201cnegative symptoms\u201d in Indications and Usage. U.S. National Library of Medicine. Accessed October 2, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?adv=1&labeltype=human&query=34067-9%3A%28negative+symptoms%29+AND+34067-9%3A%28schizophrenia%29+"},{"key":"zoi260965r5","unstructured":"Reimagine schizophrenia: transforming how we are treated, function, and thrive. Schizophrenia & Psychosis Action Alliance. February 2023. Accessed June 19, 2025. https:\/\/sczaction.org\/wp-content\/uploads\/2023\/02\/Scz-PFDD-Report-Slide-Summary-FINAL-1.pdf"},{"key":"zoi260965r20","unstructured":"Health workforce projections. Health Resources & Services Administration. Accessed February 27, 2025. https:\/\/bhw.hrsa.gov\/data-research\/projecting-health-workforce-supply-demand"},{"key":"zoi260965r44","unstructured":"Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough device designation for schizophrenia prescription digital therapeutic. Boehringer Ingelheim. Updated January 4, 2024. Accessed March 6, 2025. https:\/\/www.boehringer-ingelheim.com\/human-health\/mental-disorders\/schizophrenia\/fda-grants-breakthrough-status-schizophrenia-2"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854497\/pratap_2026_oi_260965_1790091793.36709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:30:33Z","timestamp":1790350233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854497"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.35753","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}